Who Paid My Doc
Lindsay Elbaum
Interventional Cardiology Springfield, NJ Medical Doctor
NPI 1639596984 CMS profile 8789685
211 Mountain Ave Ste 300, Springfield, NJ 07081
General payments
$27,897
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Lindsay Elbaum of Springfield, NJ is reported in the CMS Open Payments database as having received $27,897 across 119 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 80th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,110 | 21 | |
| 2024 | General | $678 | 16 | |
| 2023 | General | $655 | 8 | |
| 2022 | General | $800 | 11 | |
| 2021 | General | $1,353 | 32 | |
| 2020 | General | $23,286 | 30 | |
| 2019 | General | $15 | 1 |
Beside peers
- Lindsay Elbaum
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Lindsay Elbaum were reported at $1,110. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Lindsay Elbaum | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15 | $1,097 | $329–$3,048 | $163 |
| 2020 | $23,286 | $473 | $161–$1,480 | $114 |
| 2021 | $1,353 | $677 | $233–$1,827 | $132 |
| 2022 | $800 | $978 | $333–$2,724 | $149 |
| 2023 | $655 | $1,136 | $382–$2,986 | $160 |
| 2024 | $678 | $1,181 | $395–$3,326 | $164 |
| 2025 | $1,110 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
124
Drug cost
$48,383
Branded share of claims
36.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 17 | $20,021 | |
| Jardiance Empagliflozin | Brand | 16 | $15,676 | |
| Eliquis Apixaban | Brand | 12 | $11,973 | |
| Metoprolol Succinate | Generic | 19 | $354 | |
| Losartan Potassium | Generic | 16 | $123 | |
| Furosemide | Generic | 13 | $86 | |
| Atorvastatin Calcium | Generic | 20 | $86 | |
| Carvedilol | Generic | 11 | $65 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Records
119 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in New Jersey
Ankitkumar Patel
Interventional Cardiology · Glen Ridge, NJ
Ramin Hastings
Interventional Cardiology · Hasbrouck Heights, NJ
Michael Lim
Interventional Cardiology · Hackensack, NJ
Darshan Godkar
Interventional Cardiology · Cedar Knolls, NJ
Ryan Kaple
Interventional Cardiology · Hackensack, NJ
Matthew Saybolt
Interventional Cardiology · Eatontown, NJ
Related records
Interventional Cardiology in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.